How patient experience and real-world evidence reshape hematology advances in rare disease and blood cancers, beyond clinical end points. This commentary will appear in the May issue of Evidence-Based Oncology.
Jeff Schaffnit, MBA
Advertisement
Articles by Jeff Schaffnit, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer
2
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
3
More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor
4
Health Care Spending to Hit $9 Trillion by 2034, According to New Analysis
5